PTGX - Chief Development Officer at Protagonist Therapeutics Exercises Options Worth $281K | Benzinga
Suneel Gupta, Chief Development Officer at Protagonist Therapeutics (NASDAQ:PTGX), reported a large exercise of company stock options on October 23, according to a new SEC filing.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Gupta, Chief Development Officer at Protagonist Therapeutics, a company in the Health Care sector, just exercised stock options worth 20,000 shares of PTGX stock with an exercise price of $7.38.
Protagonist Therapeutics shares are trading down 0.0% at $14.05 at the time of this writing on Tuesday morning. Since the current price is $14.05, this makes Gupta's 20,000 shares worth $281,000.